Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics (AUTL) announces its 2022 corporate priorities, emphasizing the pivotal developments of its candidate obe-cel for adult ALL patients. The Phase 2 FELIX study anticipates data mid-2022, with patient recruitment ongoing. Management highlights the favorable safety profile from the Phase 1b portion of the trial, with no severe cytokine release syndrome noted. Additionally, financial backing of up to $250 million from Blackstone Life Sciences will aid in advancing therapeutic initiatives, including its new manufacturing facility in the UK to enhance production capabilities.
Autolus Therapeutics (Nasdaq: AUTL) announced its participation in two upcoming virtual conferences: the H.C. Wainwright BioConnect Conference on January 10, 2022, featuring Dr. Lucinda Crabtree, and the J.P. Morgan Healthcare Conference on January 12, 2022, with Dr. Christian Itin presenting. Both events will include investor meetings and will be accessible via Autolus' website, where an archived replay will be available for 90 days. Autolus is known for developing next-generation T cell therapies targeting cancer.
Autolus Therapeutics (AUTL) provided updates on its CAR T therapy, obe-cel, at the ASH 2021 Annual Meeting. The ALLCAR19 study reported a morphological event-free survival (EFS) of 46% at 24 months. Obe-cel achieved a metabolic complete response in 100% of patients with follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma, showing favorable safety with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported. The company anticipates further clinical data in 2022.
Autolus Therapeutics (Nasdaq: AUTL) will hold a conference call on December 13, 2021, at 8:00 am ET to discuss data presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14. This call reflects a timing change from the previous announcement. The call will include a webcast with accompanying slides available on the company's website. A replay of the call will be accessible for one week after.
Autolus Therapeutics plc (Nasdaq: AUTL) announced the appointment of Dr. William D. Young as a non-executive director, effective immediately. This decision follows a recent investment by Blackstone Life Sciences. Dr. Young brings over 50 years of experience in the life sciences sector, previously serving as COO of Genentech and CEO of Monogram Biosciences. His expertise is expected to enhance the commercial strategy of the company’s investigational therapy, Obe-cel, which aims to improve outcomes for adult patients with acute lymphoblastic leukemia and other cancers.
Autolus Therapeutics has published a significant article in Nature Scientific Reports detailing its controllable CAR T cell system, named TetCAR. This innovative approach allows for reversible dampening of programmed T cell activity using widely available antibiotics, tetracycline and minocycline. Such control mechanisms are crucial for managing severe adverse side effects in patients undergoing CAR T cell therapy. The company emphasizes that this method is based on established pharmacological agents, enhancing its practical application in clinical settings.
Autolus Therapeutics has announced a strategic collaboration with Blackstone Life Sciences, securing up to $250 million in financing to advance its investigational therapy, obe-cel, for adult acute lymphoblastic leukemia (ALL). The investment includes $150 million in product financing, with $50 million available at closing. Blackstone will also acquire $100 million in Autolus' American Depositary Shares. This funding aims to support clinical development and initial commercialization activities for obe-cel, which has shown potential as a curative treatment in a last-line setting.
Autolus Therapeutics plc (Nasdaq: AUTL) announced progress in its CAR T cell therapies, specifically obe-cel (AUTO1), at the 63rd ASH Annual Meeting in December 2021. The company will present an oral session on the industrialization of its Miltenyi Prodigy-Based manufacturing process and poster presentations on its AUTO1 programs for adult and pediatric Acute Lymphocytic Leukemia. A conference call is scheduled for December 14, 2021, to discuss ASH data. Autolus aims to enhance safety and efficacy through its innovative therapies designed to target cancer cells effectively.
Autolus Therapeutics (Nasdaq: AUTL) reported operational and financial results for Q3 2021, highlighting continued progress in clinical evaluations, particularly for obe-cel in the FELIX study. The expected delivery of primary endpoint data is slated for mid-2022. Cash at the end of Q3 totaled $173.1 million, down from $216.4 million in Q2 2021. The net loss attributable to ordinary shareholders was $34.0 million, an improvement from $37.3 million in 2020. The company anticipates key data presentations at the 63rd ASH Meeting in December 2021.
Autolus Therapeutics plc (Nasdaq: AUTL) announced its plan to release third quarter 2021 financial results on November 3, 2021, before U.S. markets open. The company’s management will host a conference call at 8:30 am ET to discuss the financial results and provide a business update. Interested parties can access the webcast through the company’s events section on its website. The call can also be dialed in using provided numbers for U.S. and international callers with a reference conference ID of 6984737.